



**ASX Announcement**  
**6 May 2021**

## **APPOINTMENT OF NEW NON-EXECUTIVE DIRECTOR**

The Board of Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'OptiScan') is delighted to announce the appointment of Professor Camile Farah as a non-executive director of the Company. He has been nominated to the board by Orchid Capital Investments Pte Ltd (Orchid) pursuant to the subscription agreement signed by the Company and Orchid on 21 September 2020.

Professor Farah is a highly accomplished executive, academic, researcher and author with 25 years' experience in the healthcare, biotech and medical research sectors. He is dual trained physician and pathologist, with public and private appointments at Fiona Stanley Hospital, Hollywood Private Hospital, Qscan Radiology Clinics, Australian Clinical Labs, and Genomics for Life. Professor Farah is a leading Australian expert in oral cancer and precancerous pathology based on his clinical and research expertise having published 250 clinical and scientific articles and a bestselling textbook. He is a former Dean at the University of Western Australia, and currently an Adjunct Professor at CQ University and an Honorary Professorial Research Fellow at the Peter MacCallum Cancer Centre. In addition to managing his own consulting business, he is Executive Director of the Australian Centre for Oral Oncology Research & Education which undertakes cutting edge research in head and neck cancer.

**Professor Farah said: "I am excited to join the Board of the Company and to support the research, development and commercialisation of OptiScan's one-of-a-kind confocal technology and improve the outcomes for cancer patients world-wide. My appointment with OptiScan brings together my passion for science, technology and healthcare. Based on my experience with optical imaging, digital pathology, and precision medicine, and as a long time user of OptiScan's technology, I am confident that OptiScan's InVivage™ device has the opportunity to revolutionise the standard of care for early cancer detection and treatment."**

Robert Cooke, the non-executive Chair of OptiScan said:

**"Professor Farah is an eminent clinician scientist who will bring a wealth of knowledge to the OptiScan board. He has extensive experience in various optical imaging technologies, clinical practice and medtech research, and will be extremely valuable as we undertake the regulatory approvals and commercial roll-out of our InVivage™ device globally. Professor Farah is one of the world's leading oral oncology clinicians and researchers at the forefront of the development and use of new technologies with a network of international research collaborations."**

Professor Farah's Appendix 3X is attached to this announcement.

- ends -

This announcement has been authorised for release by the Board of OptiScan.

**For investor queries, please contact:**

Darren Lurie  
Managing Director – OptiScan Imaging  
E: [dlurie@Optiscan.com](mailto:dlurie@Optiscan.com)

**Phone** (61 3) 9538 3333

**Website** [www.OptiScan.com](http://www.OptiScan.com)

PO Box 1066, Mt Waverley MDC VIC 3149 Australia

## About Optiscan

OptiScan is a global leader in the development of microscopic imaging and related technologies for surgery and medical research. Based in Victoria, Australia, OptiScan was established in 1994, and listed on the ASX in 1997 (ASX: OIL). OptiScan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level – instant “virtual biopsies” for cancer screening, diagnoses and in surgery.

## Disclaimer

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.*

**Phone** (61 3) 9538 3333

**Website** [www.OptiScan.com](http://www.OptiScan.com)

PO Box 1066, Mt Waverley MDC VIC 3149 Australia

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Optiscan Imaging Limited
<b>ABN</b>	81 077 771 987

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Prof Camile Farah
<b>Date of appointment</b>	6 May 2021

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Nil

## Appendix 3X

### Initial Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Number & class of Securities
Phoenix Financial Pty Ltd <Phoenix Super Fund A/C> (Prof Farah is a beneficiary of the fund)	500,000 Fully paid ordinary shares
Dr Marie Anne Teresa J Matias (Spouse of Mr Farah)	20,224 Fully paid ordinary shares

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

---

+ See chapter 19 for defined terms.